Investigating the SMA's Role in Speech and Reading Fluency in PWS With rTMS (NCT06809387) | Clinical Trial Compass
By InvitationNot Applicable
Investigating the SMA's Role in Speech and Reading Fluency in PWS With rTMS
Turkey (Türkiye)15 participantsStarted 2025-01-01
Plain-language summary
The goal of this clinical trial is to study how a part of the brain called the supplementary motor area (SMA) is connected to speech and reading fluency in adults who stutter. Researchers will use a method called repetitive transcranial magnetic stimulation (rTMS) to learn more about this relationship. The main question it aims to answer is:
-Will participants' speech and reading fluency improve when we stimulate the SMA with rTMS?
Participants will take part in both placebo rTMS and real rTMS sessions.
Participants will:
* Come to the research center for 2 days, with at least a one-week break between visits
* Read 4 passages and speak on 4 topics
* Be video recorded while doing these tasks
Who can participate
Age range
18 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* To be over 18 years of age
* Presence of developmental stuttering
* Being right hand dominant
Exclusion Criteria:
* Being under 18 years of age
* The presence of a diagnosed brain lesion
* Presence of intracranial metal implantation
* Presence of a speech and language problem other than stuttering
* The presence of a diagnosed neurological disorder
* The presence of a diagnosed psychiatric disorder
* Use of drugs and substances that may affect the central nervous system
* History of epilepsy
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Severity of stuttering in speech and reading Day 1 (pre-treatment)
Timeframe: Immediately before the treatment (Day 1)
2
Severity of stuttering in speech and reading Day 1 (post-treatment)
Timeframe: Immediately after the treatment (Day 1)
3
Severity of stuttering in speech and reading Day 2 (pre-treatment)
Timeframe: Immediately before the treatment (Day 2)
4
Severity of stuttering in speech and reading Day 2 (post-treatment)
Timeframe: Immediately after the treatment (Day 2)